ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out if the combination of ABT-888 and
temozolomide is safe and effective in treating patients with metastatic breast cancer.
ABT-888 works by obstructing a DNA enzyme called poly (ADP-ribose) polymerase (PARP) which
helps repair cancer cells damaged by chemotherapy. By blocking the PARP enzyme, the cancer
cells are unable to repair themselves and as a result die. The other drug in this study is
temozolomide. Temozolomide is designed to damage DNA in order to prevent cancer cells from
reproducing. Because PARP inhibitors, such as ABT-888, prevent cancer cells from repairing
their own DNA, they enhance the potential of chemotherapy therapy like temozolomide to induce
cell death. The combination of ABT-888 and temozolomide has been used in a clinical trial for
treatment of other cancers and information for this research study suggests that the
combination may help to inhibit growth in breast cancer.
ONLY THE EXPANSION COHORT BELOW IS RECRUITING:
BRCA CARRIER EXPANSION COHORT: The purpose of the expansion cohort is to further evaluate the
activity and safety of this combination in BRCA mutation carriers with metastatic breast
cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Steven Isakoff, MD, PhD Steven J Isakoff, MD, PhD
Collaborators:
Abbott Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute